Correction to: International Journal of Hematology (2020) 111:724–732 https://doi.org/10.1007/s12185-019-02810-y
In the original publication of the article, the “Conflict of Interest” has been published incorrectly. The corrected version is given below.
Conflict of interest: M. Nishikori receives honoraria from Eisai and funding from Eisai and Sumitomo Dainippon Pharmaceutical. A. Takaori-Kondo receives honoraria from Celgene, Bristol-Myers Squibb, Novartis, MSD, Kyowa Kirin, Asteras, and funding from Celgene, Ono, COGNANO, Thyas, Bristol-Myers Squibb, and has research support from Ono, Takeda, Chugai, Eisai, Nippon Shinyaku, Asteras, Kyowa Kirin, Otsuka, Pfizer, Popuri, Ohara, Sanofi, and Kim’s Korean Ginseng. All other authors do not have any conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Tamura, N., Maeda, H., Nishikori, M. et al. Correction to: Histologic transformation of t(11;18)-positive MALT lymphoma presented with aberrant T-cell marker expression. Int J Hematol 112, 265 (2020). https://doi.org/10.1007/s12185-020-02924-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-020-02924-8